Physician profile
Jessica Tapp
NPI 1093346769
$4,348.98
in general payments reported to CMS, 2019-2025
40 companies · $1,532 in 2025
The $1,532 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $206 · 2022: $148 · 2023: $1,114 · 2024: $1,350 · 2025: $1,532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,978 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,977.75 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $814.48 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $630.05 | 2023-2025 | |
| Amgen INC. | $334.36 | 2023-2025 | Evenity, Prolia, Repatha |
| Phathom Pharmaceuticals, INC. | $239.95 | 2024 | Voquezna |
| Pfizer INC. | $232.85 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $206.78 | 2021-2025 | Airsupra, Evusheld, Breztri |
| Axsome Therapeutics, INC. | $153.29 | 2025 | Auvelity |
| Actelion Pharmaceuticals US, INC. | $141.47 | 2021-2025 | Opsumit, Uptravi |
| Jazz Pharmaceuticals INC. | $128.91 | 2021-2025 | |
| Pharming Healthcare, INC. | $124.99 | 2024 | Ruconest |
| Mallinckrodt Hospital Products INC. | $120.17 | 2025 | Acthar |
| Lilly USA, LLC | $116.56 | 2023-2024 | Mounjaro |
| Exact Sciences Corporation | $104.77 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $87.65 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.62 | 2021-2025 | Glassia, Hyqvia |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $80.44 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $70.74 | 2022-2023 | Quviviq |
| Mylan Specialty L.P. | $70.53 | 2024 | Yupelri |
| Astellas Pharma US INC | $58.00 | 2023-2024 | Veozah |
| Almatica Pharma LLC | $55.03 | 2023-2024 | Gralise, Loreev Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.44 | 2021-2025 | Jascayd |
| Abbott Laboratories | $36.70 | 2023-2025 | Id Now Instrument, Freestyle Libre 3 |
| Harmony Biosciences LLC | $34.19 | 2022 | |
| Glaxosmithkline, LLC. | $33.88 | 2023-2025 | Trelegy Ellipta |
| Evoke Pharma, INC. | $33.83 | 2025 | |
| Dexcom, INC. | $32.03 | 2024-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $30.17 | 2021 | |
| Xeris Pharmaceuticals, INC. | $23.17 | 2024 | Recorlev |
| Hologic Sales and Service, LLC | $23.14 | 2023 | Aptima, Thinprep 2000 Processor |
| Globus Medical, INC. | $21.77 | 2025 | Senza |
| Genzyme Corporation | $21.60 | 2025 | |
| Paratek Pharmaceuticals, INC. | $20.97 | 2021 | |
| Alnylam Pharmaceuticals INC. | $20.53 | 2024 | Givlaari |
| Cvrx, INC. | $19.03 | 2024 | Barostim Neo System |
| Regeneron Healthcare Solutions, INC. | $18.60 | 2025 | Dupixent |
| Insmed, INC. | $17.38 | 2025 | Brinsupri |
| Tactile Systems Technology INC | $16.52 | 2025 | Nimbl, Flexitouch Plus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.68 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $12.99 | 2023 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Tapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.